Status: Recruiting
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
Participants needed: 138
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Dompé Farmaceutici S.p.AUpdated: Apr 20, 2026Locations: 19
Eligibility criteria
Men or women aged ≥ 18 and ≤ 65 years of age. [+6]
Inability to speak and understand the local language sufficiently to understand... [+6]